New Interaction-Parasite Reduction Ratio Assay for Early Derisk in Clinical Development of Antimalarial Combinations.

The development and spread of drug-resistant phenotypes substantially threaten malaria control efforts. Combination therapies have the potential to minimize the risk of resistance development but require intensive preclinical studies to determine optimal combination and dosing regimens. To support the selection of new combinations, we developed a novel combination approach to help identify the pharmacodynamic interactions of the two antimalarial drugs in a combination which can be plugged into a pharmacokinetic/pharmacodynamic model built with human monotherapy parasitological data to predict the parasitological endpoints of the combination. This makes it possible to optimally select drug combinations and doses for the clinical development of antimalarials. With this assay, we successfully predicted the endpoints of two phase 2 clinical trials in patients with the artefenomel-piperaquine and artefenomel-ferroquine drug combinations. In addition, the predictive performance of our novel model was equivalent to that of the humanized mouse model outcome. Last, our more informative combination assay provided additional insights into the pharmacodynamic drug interactions compared to the systems, e.g., a concentration-dependent change in the maximum killing effect () and the concentration producing 50% of the killing maximum effect (EC) of piperaquine or artefenomel or a directional reduction of the EC of ferroquine by artefenomel and a directional reduction of of ferroquine by artefenomel. Overall, this novel -based technology will significantly improve and streamline the economic development of new drug combinations for malaria and potentially also in other therapeutic areas.